Hims & Hers Health, Inc. Class A Common Stock is the equity of Hims & Hers Health, a consumer-focused digital health and telehealth platform. Hims & Hers connects customers with licensed healthcare professionals through its websites and mobile app, offering online consultations, prescriptions, laboratory testing, and follow-up support. Its current product and service lineup spans sexual health, hair care, mental health, weight loss, dermatology, and general wellness, with a mix of prescription and over-the-counter offerings. The company also provides personalized health solutions and fulfillment services through its branded consumer platform. Based in San Francisco and founded in 2017, Hims & Hers operates in the healthcare market as a direct-to-consumer service provider that combines clinical access, digital technology, and pharmacy-enabled delivery.
Omsætning og resultat (USD)
Gns. kursmål: $31,15

Hims & Hers Stock Just Plummeted 17%. Is the Stock a Buy Ahead of a Peptide Push?
The Motley Fool · 13. nov. 2026

HIMS Partners With Lilly to Offer FDA-Approved Weight-Loss Drugs
Zacks Investment Research · 13. nov. 2026

Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It
Zacks Investment Research · 13. nov. 2026
Hims & Hers Health, Inc. Class A Common Stock is the equity of Hims & Hers Health, a consumer-focused digital health and telehealth platform. Hims & Hers connects customers with licensed healthcare professionals through its websites and mobile app, offering online consultations, prescriptions, laboratory testing, and follow-up support. Its current product and service lineup spans sexual health, hair care, mental health, weight loss, dermatology, and general wellness, with a mix of prescription and over-the-counter offerings. The company also provides personalized health solutions and fulfillment services through its branded consumer platform. Based in San Francisco and founded in 2017, Hims & Hers operates in the healthcare market as a direct-to-consumer service provider that combines clinical access, digital technology, and pharmacy-enabled delivery.
Omsætning og resultat (USD)
Gns. kursmål: $31,15

Hims & Hers Stock Just Plummeted 17%. Is the Stock a Buy Ahead of a Peptide Push?
The Motley Fool · 13. nov. 2026

HIMS Partners With Lilly to Offer FDA-Approved Weight-Loss Drugs
Zacks Investment Research · 13. nov. 2026

Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It
Zacks Investment Research · 13. nov. 2026